Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates

EDIT-401 on track for human proof-of-concept data by end of 2026

Read more at globenewswire.com